hysitrack PLC ("Physitrack" or the "Company") announces that, further to the share buy-back programme announced on 21 July 2026 and commenced on 10 August 2026, it has repurchased shares under the programme during the week of 26–30 October 2026.
Summary of transactions
| Period | Total shares repurchased during the week | Volume-weighted average price paid (SEK) | Total consideration paid (SEK) | Total shares held by the Company (treasury) following these transactions | Total outstanding shares in the Company | Treasury holding as % of issued share capital |
| 26–30 October 2026 | 3,900 | 12.7987 | 49,915.04 | 72,637 | 16,260,766 | 0.4467% |
Individual transactions
| Date | Quantity | Average price (SEK) |
| 2026-10-26 | 1,500 | 12.90 |
| 2026-10-27 | 0 | n/a |
| 2026-10-28 | 800 | 12.9625 |
| 2026-10-29 | 800 | 12.8875 |
| 2026-10-30 | 800 | 12.3563 |
No notification of any trade was received from Pareto Securities for 27 October 2026. The cumulative "Total shares held by the Company" figures reported on 26 and 28 October reconcile exactly on the assumption that zero shares were purchased on 27 October; this has not been separately confirmed by Pareto as an explicit nil return and is flagged for confirmation.
Regulatory basis
These transactions were effected under the safe harbour provided by Article 5 of the Market Abuse Regulation (EU) 596/2014 ("MAR") and Commission Delegated Regulation (EU) 2016/1052, for the purpose of meeting the Company's obligations under its employee share plans. The purchases were executed by Pareto Securities on a non-discretionary basis on Nasdaq First North Growth Market Stockholm.
Notification details
| # | Detail |
| 1. Issuer | Physitrack PLC; LEI 213800PC4QYNWHPCP774 |
| 2. Instrument/ISIN | Ordinary shares / GB00BYX22590 |
| 3. Trading venue | Nasdaq First North Growth Market Stockholm (PTRK) |
| 4. Currency | SEK |
| 5. Purpose | To meet the Company's obligations under its employee share plans, permitted under Article 5(2) MAR |
| 6. Executing broker | Pareto Securities, non-discretionary mandate |
This disclosure is made in accordance with Article 5(3) of MAR and Commission Delegated Regulation (EU) 2016/1052.